Anzeige
Mehr »
Login
Dienstag, 29.11.2022 Börsentäglich über 12.000 News von 681 internationalen Medien
Breaking News! Rallye und Ausbruch die logische Konsequenz?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J9WY ISIN: FR0004197747 Ticker-Symbol: 4W6 
Frankfurt
29.11.22
17:04 Uhr
2,265 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
THERADIAG SA Chart 1 Jahr
5-Tage-Chart
THERADIAG SA 5-Tage-Chart
RealtimeGeldBriefZeit
2,2252,32022:56

Aktuelle News zur THERADIAG Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.10.Theradiag: Downward Adjustment of the Sales and Profitability Targets For 2026258Regulatory News: THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and Theranostics, is adjusting its 2026 sales and profitability targets. During...
► Artikel lesen
30.09.Theradiag: Appointment of an Independent Expert283Regulatory News: THERADIAG (ISIN: FR0004197747, Ticker: ALTER) (Paris:ALTER), a company specializing in in vitro diagnostics and Theranostics, announces the appointment of Crowe HAF by the Company's...
► Artikel lesen
23.09.Theradiag Announces That Biosynex Has Filed a Voluntary Takeover Bid for Its Shares596Regulatory News: THERADIAG (ISIN: FR0004197747, Ticker: ALTER) (Paris:ALTER), a company specializing in in vitro diagnostics and Theranostics, announces that Biosynex (ISIN: FR0011005933 Mnemonic:...
► Artikel lesen
19.09.Theradiag Announces Its Results for the First Half of 2022: Breaking-Even and Confirming Its Ability to Be Structurally Profitable From Early 2023312Regulatory News: THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and Theranostics, today announces its half-year results to June 30, 2022, as approved...
► Artikel lesen
THERADIAG Aktie jetzt für 0€ handeln
18.07.Theradiag Reports Revenue of €6.3 Million for the First Half of 2022, Up 14.3%382Solid growth of 9.3% for Theranostics Strong growth of 19.3% in IVD (In Vitro Diagnostics) activity Cash position of €6.0 million on June 30, 2022, in line with the budget Regulatory...
► Artikel lesen
08.06.Quotient Limited and Theradiag Announce Partnership to Advance Autoimmune Disease Diagnostics454Partnership brings together novel technology and clinical applications expertise to produce automated, multiplexed solutions for advancing autoimmune diagnostics Expands access to $2 billion...
► Artikel lesen
31.05.THERADIAG Announces the Launch of ez-Track1, a Point-of-Care Testing Solution for Therapeutic Drug Monitoring306Regulatory News: THERADIAG (ISIN: FR0004197747, Mnemonic: ALTER), a company specializing in in vitro diagnostics and theranostics, announces the launch of ez-Track1, a real Point-of-Care Testing...
► Artikel lesen
19.05.Theradiag Announces the Launch of Two New i-Tracker Kits340Regulatory News: THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and Theranostics, today announces the launch of two additional kits...
► Artikel lesen
06.05.Theradiag: Report of the Ordinary and Extraordinary General Meeting of 5 May 2022257New terms of office for Mr Pierre MORGON as Director and Chairman of the Board of directors Appointment of Mr Larry ABENSUR, Mr Thomas LAMY and Mr Thierry PAPER as new directors Regulatory...
► Artikel lesen
30.03.Theradiag: Change in the Composition of the Board of Directors to Be Voted on at the Annual General Meeting of May 5, 2022265Regulatory News: THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, today announced that a change in the composition of its Board of...
► Artikel lesen
21.03.Theradiag Announces Its 2021 Full-Year Results360Revenue growth of 6.8%, driven by the solid performance of Theranostics, up 13% 2021 net result of €767 thousand, impacted by exceptional expenses of €496 thousand H2 2021 net result...
► Artikel lesen
31.01.Theradiag: THERADIAG Posts 2021 Revenue of €11.1 Million, up 7%286Excellent performance for Theranostics sales, up 13% Further expansion in activity in the United States, with growth of 17% Growth in the Company's historical IVD activity Cash...
► Artikel lesen
13.01.Theradiag: Signing of a Distribution Agreement with BIOSYNEX of Their AMPLIQUICK SARS-CoV-2 PCR Test465Regulatory News: THERADIAG (ISIN: FR0004197747, Mnémonique: ALTER), a company specializing in in vitro diagnostics of autoimmune diseases and theranostics, and BIOSYNEX (ISIN: FR0011005933, Mnémonique:...
► Artikel lesen
08.12.21THERADIAG Announces Its 2022 Financial Calendar327Regulatory News: THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics of autoimmune diseases and theranostics, today announces its schedule...
► Artikel lesen
02.12.21THERADIAG Announces the Launch of 4 New i-Tracker Kits and the Validation of a New Parameter in the United States320Regulatory News: THERADIAG (ISIN: FR0004197747, Ticker: ALTER) (Paris:ALTER), a company specializing in in vitro diagnostics and Theranostics, today announces the launch of four additional kits...
► Artikel lesen
30.11.21Theradiag: THERADIAG notes the acquisition of a stake in its capital by BIOSYNEX440Regulatory News: THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and Theranostics, today announces that it has received yesterday a...
► Artikel lesen
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1